Allianca Saude e Participacoes SA - ALLIAR

Allianca Saude e Participacoes SA - ALLIAR

0.95
BRL
-0.36
(-27.48%)
-8.93EPS
769.23MMarket Cap
Mar 17Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.96
7.59
9.41
9.23
9.11
9.09
7.87
9.67
9.21
9.97
9.95
7.57
7.57
Basic EPS, GAAP
-0.07
-0.14
0.15
0.06
0.34
0.35
-0.83
-0.05
-1.93
-1.93
-1.09
-9.01
-9.01
Free Cash Flow per Basic Share
-1.38
-0.05
-0.26
-0.13
0.64
1.17
0.43
0.41
0.63
0.09
-1.19
0.81
0.81
Dividend per Share
0.69
- -
- -
- -
0.03
0.19
0.05
0.02
0.02
0.13
- -
0.11
0.02
Book Value per Share
6.49
6.4
10.24
10.32
10.65
10.86
10.09
9.99
8.06
7.77
9.26
-1.82
-1.82
Tangible Book Value per Share
0.96
0.81
2.58
2.14
2.45
2.68
1.91
1.7
-0.33
-0.72
0.77
-3.65
-3.65
Basic Weighted Avg Shares
57
92
101
117
118
118
118
118
118
118
118
152
152
Sales/Revenue/Turnover
393
700
951
1,078
1,077
1,073
929
1,137
1,085
1,180
1,178
1,154
1,154
Operating Margin (%)
7.58
15.54
9.51
5.24
11.37
11.69
-2.3
7.23
-3.97
2.78
9.67
-90.34
-90.34
Depreciation Expense
37
36
54
79
83
118
119
120
118
93
102
90
90
Net Income, GAAP
-4
-13
15
7
40
41
-97
-6
-228
-228
-129
-1,372
-1,372
Effective Tax Rate (%)
- -
264.02
16.9
- -
26.38
23.79
- -
19.06
- -
- -
- -
- -
- -
Profit Margin (%)
-1.06
-1.82
1.55
0.62
3.72
3.85
-10.49
-0.49
-21
-19.32
-10.97
-118.94
-118.94
Working Capital
15
29
90
40
15
11
92
-100
-194
-210
28
-1,279
-1,279
LT Debt
240
386
303
432
373
556
743
674
877
902
644
195
195
Total Equity
743
733
1,212
1,270
1,300
1,320
1,224
1,209
982
944
1,137
-252
-252
Return on Invested Capital (%)
- -
-15.51
5.71
- -
5.35
4.71
- -
2.89
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-9.64
3.89
- -
3.52
3.91
- -
2.42
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-1.73
1.55
0.56
3.24
3.25
-7.88
-0.48
-21.44
-24.41
-12.83
- -
- -

Capital Structure

BRL

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
223
253
502
LT Borrowings
232
250
5
LT Finance Leases
198
214
190
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
152
152
152
Market Capitalization
757
996
769

Working Capital

BRL

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
742
811
507
Cash, Cash Equivalents & STI
158
171
61
Accounts Receivable, Net
181
199
184
Inventories
10
13
9
Total Current Liabilities
714
807
1,786
Payables & Accruals
- -
- -
- -
ST Debt
223
253
502
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.89%
-25.12%
-122.19%
Free Cash Flow
-172.74%
-325.43%
-187.49%
Net Income, GAAP
467.42%
955.05%
962.85%
Sales/Revenue/Turnover
5.97%
4.87%
-2.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
290
299
302
288
1,180
2024
281
318
318
301
1,178
2025
307
304
328
215
1,154

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.31
-0.44
-0.44
-0.75
-1.93
2024
-0.67
- -
0.02
-0.45
-1.09
2025
-0.13
-0.1
0.05
-8.83
-9.01

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.13
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
0.02
0.11

Company Description

CEO
Isabella Tanure Correa
Full Time Employees
5,800
Sector
Health services
Industry
Medical/Nursing services
Address
Street Afonso de Freitas, 59 - Paraíso São Paulo SP Brazil 04006-050
IPO Date
Oct 28, 2016
Business
Alliança Saúde e Participações S.A. functions as a diversified holding entity, primarily dedicated to delivering comprehensive medical diagnostic services across Brazil. The company provides a broad spectrum of offerings, encompassing advanced diagnostic imaging, clinical analysis, nuclear medicine, and genetic testing, alongside vaccination services. Headquartered in São Paulo, Brazil, the firm has expanded its footprint significantly, operating over 120 service units in numerous cities across 13 states. Established in 1992, the company recently embarked on a new phase of strategic growth, marked by significant acquisitions like Grupo Meddi in 2025 and an increased focus on B2B partnerships and technological innovations in remote diagnostics.